

East Kent Prescribing Group

Withdrawal of Bimatoprost Eye Drops 300mcg/ml (0.03%)

Recommendation

Bimatoprost eye drops 300mcg/ml (0.03%) were discontinued on 1st July 2015. The manufacturers Allergan have confirmed that bimatoprost 100mcg/ml (0.01%) has been shown to be equivalent to the 300mcg/ml (0.03%) formulation in IOP lowering efficacy and demonstrated an improved tolerability profile in terms of hyperaemia severity, ocular adverse events and subsequent patient discontinuations.

The equipotency is achieved by an increased concentration of benzalkonium chloride in the 100mcg/ml formulation.

EKHFT opthalmologists have confirmed that patients can be changed from 300mcg/ml to the 100mcg/ml eye drops.

Provided on behalf of: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)

Date: October 2015

Address: c/o Canterbury and Coastal CCG, Ground Floor, Council Offices, Military Road, Canterbury,

Kent, CT1 1YW

Contact: T: 01227 791267 | E: accg.eastkentprescribing@nhs.net

Page 1 of 1